| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH |
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Medicinal Chemistry and Pharmacognosy, College of Pharmacy, and Hormones and Cancer Program, Ohio State University Comprehensive Cancer Center, The Ohio State University, Columbus, Ohio 43210
* To whom correspondence should be addressed. E-mail: Brueggemeier.1{at}osu.edu.
Estradiol, the most potent endogenous estrogen, is biosynthesized from androgens by the cytochrome P450 enzyme complex called aromatase. Aromatase is present in breast tissue, and intratumoral aromatase is the source of local estrogen production in breast cancer tissues. Inhibition of aromatase is an important approach for reducing growth-stimulatory effects of estrogens in estrogen-dependent breast cancer. Steroidal inhibitors that have been developed to date build upon the basic androstenedione nucleus and incorporate chemical substituents at varying positions on the steroid. Nonsteroidal aromatase inhibitors can be divided into three classes: aminoglutethimide-like molecules, imidazole/triazole derivatives, and flavonoid analogs. Mechanism-based aromatase inhibitors are steroidal inhibitors that mimic the substrate, are converted by the enzyme to a reactive intermediate, and result in the inactivation of aromatase. Both steroidal and nonsteroidal aromatase inhibitors have shown clinical efficacy in the treatment of breast cancer. The potent and selective third-generation aromatase inhibitors, anastrozole, letrozole, and exemestane, were introduced into the market as endocrine therapy in postmenopausal patients failing antiestrogen therapy alone or multiple hormonal therapies. These agents are currently approved as first-line therapy for the treatment of postmenopausal women with metastatic estrogen-dependent breast cancer. Several clinical studies of aromatase inhibitors are currently focusing on the use of these agents in the adjuvant setting for the treatment of early breast cancer. Use of an aromatase inhibitor as initial therapy or after treatment with tamoxifen is now recommended as adjuvant hormonal therapy for a postmenopausal woman with hormone-dependent breast cancer.
This article has been cited by other articles:
 |
|
 |
|
  W. R. Miller, J. Bartlett, A. M. H. Brodie, R. W. Brueggemeier, E. di Salle, P. E. Lonning, A. Llombart, N. Maass, T. Maudelonde, H. Sasano, et al. Aromatase Inhibitors: Are There Differences Between Steroidal and Nonsteroidal Aromatase Inhibitors and Do They Matter? Oncologist, August 1, 2008; 13(8): 829 - 837. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Matsumoto, Y. Yamaguchi, Y. Seino, A. Hatakeyama, H. Takei, H. Niikura, K. Ito, T. Suzuki, H. Sasano, N. Yaegashi, et al. Estrogen signaling ability in human endometrial cancer through the cancer-stromal interaction Endocr. Relat. Cancer, June 1, 2008; 15(2): 451 - 463. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. B. Michaud Treatment-experienced breast cancer Am. J. Health Syst. Pharm., May 15, 2008; 65(10_Supplement_3): S4 - S9. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 X. Wang, S. Masri, S. Phung, and S. Chen The Role of Amphiregulin in Exemestane-Resistant Breast Cancer Cells: Evidence of an Autocrine Loop Cancer Res., April 1, 2008; 68(7): 2259 - 2265. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I Svechnikova, K Svechnikov, and O Soder The influence of di-(2-ethylhexyl) phthalate on steroidogenesis by the ovarian granulosa cells of immature female rats J. Endocrinol., September 1, 2007; 194(3): 603 - 609. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Lin, O. Ercan, J. Raza, C. P. Burren, S. M. Creighton, R. J. Auchus, M. T. Dattani, and J. C. Achermann Variable Phenotypes Associated with Aromatase (CYP19) Insufficiency in Humans J. Clin. Endocrinol. Metab., March 1, 2007; 92(3): 982 - 990. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Hong, B. Yu, M. Sherman, Y.-C. Yuan, D. Zhou, and S. Chen Molecular Basis for the Aromatization Reaction and Exemestane-Mediated Irreversible Inhibition of Human Aromatase Mol. Endocrinol., February 1, 2007; 21(2): 401 - 414. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. Supornsilchai, O. Soder, and K. Svechnikov Stimulation of the pituitary-adrenal axis and of adrenocortical steroidogenesis ex vivo by administration of di-2-ethylhexyl phthalate to prepubertal male rats J. Endocrinol., January 1, 2007; 192(1): 33 - 39. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Hartman, K. Lindberg, A. Morani, J. Inzunza, A. Strom, and J.-A. Gustafsson Estrogen Receptor {beta} Inhibits Angiogenesis and Growth of T47D Breast Cancer Xenografts Cancer Res., December 1, 2006; 66(23): 11207 - 11213. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
X. Wang and S. Chen Aromatase Destabilizer: Novel Action of Exemestane, a Food and Drug Administration-Approved Aromatase Inhibitor Cancer Res., November 1, 2006; 66(21): 10281 - 10286. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Cowey and R. W. Hardy The Metabolic Syndrome: A High-Risk State for Cancer? Am. J. Pathol., November 1, 2006; 169(5): 1505 - 1522. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Perez-Palacios, R. Santillan, R. Garcia-Becerra, E. Borja-Cacho, F. Larrea, P. Damian-Matsumura, L. Gonzalez, and A. E Lemus Enhanced formation of non-phenolic androgen metabolites with intrinsic oestrogen-like gene transactivation potency in human breast cancer cells: a distinctive metabolic pattern. J. Endocrinol., September 1, 2006; 190(3): 805 - 818. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. J. Handelsman The Rationale for Banning Human Chorionic Gonadotropin and Estrogen Blockers in Sport J. Clin. Endocrinol. Metab., May 1, 2006; 91(5): 1646 - 1653. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Suzuki, Y. Miki, Y. Nakamura, T. Moriya, K. Ito, N. Ohuchi, and H. Sasano Sex steroid-producing enzymes in human breast cancer Endocr. Relat. Cancer, December 1, 2005; 12(4): 701 - 720. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 V. Goffin, S. Bernichtein, P. Touraine, and P. A. Kelly Development and Potential Clinical Uses of Human Prolactin Receptor Antagonists Endocr. Rev., May 1, 2005; 26(3): 400 - 422. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. R. Simpson, M. Misso, K. N. Hewitt, R. A. Hill, W. C. Boon, M. E. Jones, A. Kovacic, J. Zhou, and C. D. Clyne Estrogen--the Good, the Bad, and the Unexpected Endocr. Rev., May 1, 2005; 26(3): 322 - 330. [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH |
| Endocrinology | Endocrine Reviews | J. Clin. End. & Metab. |
| Molecular Endocrinology | Recent Prog. Horm. Res. | All Endocrine Journals |
